J.Jpn. Surg. Soc.. 82(4): 324-336, 1981
Original article
COMPARISON OF ANTITUMOR EFFECT OF TWO DISTINCT IMMUNO POTENTIATING AGENTS ON A SYNGENEIC SOLID TUMOR TRANSPLANTED TO NU/NU OR NU/+MICE
|
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan (Director: Prof. Osahiko Abe) Yoshinori Yamada |
Either drug showed no effect on the growth of KKN-1 transplanted to nu/nu mice, whereas both drugs inhibited the tumor growth in nu/+ mice. These results indicated the importance of T cell function of the mice in the antitumor effect of both drugs. This was also suggested by the results that impaired blastogenic response to PHA or Con A of spleen cells from tumor-bearing nu/+ mice was significantly recovered by treatment of the mice with either drug. Winn's tumor neutralizing assay also showed antitumor activity of spleen cells of tumor-bearing nu/+ mice treated with OK-432.
Administration of either drug daily from 1 day to 5 days after tumor transplantation showed pronounced antitumor effect, whereas the same dose given from 6 days to 10 days after the transplantation showed reduced effect. OK-432, but not levamisole was effective even when the drug was given daily for 5 days before the tumor tramplantation.
Combined immunochemotherapy using OK-432 and mitomycin-C (MMC) showed synergistic effect when OK-432 was administered after MMC, while no additive effect was obtained when the sequence of the administration of the two drugs was reversed. Additive effect was observed when levamisole was combined with MMC, regardless of the sequence of the administration.
To read the PDF file you will need Adobe Reader installed on your computer.